Editorial: Advancements in drug development: exploring bi-specific antibodies as promising therapeutic strategies in oncology

Editorial: Advancements in drug development: exploring bi-specific antibodies as promising therapeutic strategies in oncology

Saved in:

Bibliographic Details
Main Authors:	Urs M. Weber, Julie M. Bailis, Angela Coxon, Sharon R. Pine, Giuseppe Giaccone
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	bi-specific antibodies T-cell engager (TCE) NK cell engager (NKCE) drug development oncology
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1651944/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment
by: Hyukmin In, et al.
Published: (2025-02-01)

Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
by: An Zhu, et al.
Published: (2024-11-01)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Joshua D Freedman, et al.
Published: (2017-06-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody
by: Liu Chen, et al.
Published: (2025-06-01)

Natural killer cell engagers for cancer immunotherapy
by: Shahryar Khoshtinat Nikkhoi, et al.
Published: (2025-01-01)

ADCs and TCE in SCLC Therapy: The Beginning of a New Era?
by: Paola Muscolino, et al.
Published: (2025-04-01)

Flow cytometry analysis of cytotoxic cells in patients with chronic hepatitis C
by: M. S. Selkova
Published: (2014-09-01)

Strategies for clinical dose optimization of T cell-engaging therapies in oncology
by: Kathryn Ball, et al.
Published: (2023-12-01)

Corrigendum: Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases
by: Luca Perico, et al.
Published: (2025-01-01)

Bispecific antibodies: unleashing a new era in oncology treatment
by: Lin Shui, et al.
Published: (2025-08-01)

Factors Influencing Removal of Trichloroethylene in a Zero-Valent Iron Fenton System
by: Yangyang Sun, et al.
Published: (2025-04-01)

CAR-NK cell therapy: promise and challenges in solid tumors
by: Sahar Balkhi, et al.
Published: (2025-04-01)

PECULIARITIES OF NK CELLS DIFFERENTIATION: CD56dim AND CD56bright NK CELLS AT PREGNANCY AND IN NON-PREGNANT STATE
by: V. A. Mikhailova, et al.
Published: (2017-01-01)

Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies
by: Marwin Groener, et al.
Published: (2025-07-01)

Whose Responsibility Is It? Implementing Patient-Prioritized Healthcare System Change in Oncology
by: Holly Etchegary, et al.
Published: (2024-11-01)

Innovative strategies for T cell engagers for cancer immunotherapy
by: Cristina Bergamaschi, et al.
Published: (2025-12-01)

Primary extranodal NK/T cell lymphoma of stomach: A case report and review of literature
by: Prashant Mane, et al.
Published: (2023-07-01)

Primary extranodal NK/T cell lymphoma of stomach: A case report and review of literature
by: Prashant Mane, et al.
Published: (2024-04-01)

CAR-NK cells derived from cord blood originate mainly from CD56−CD7+CD34−HLA-DR−Lin− NK progenitor cells
by: Tansri Wibowo, et al.
Published: (2024-12-01)

NK cells expansion <i>in vitro</i> is followed by loss of inhibitory KIR expression
by: N. A. Alekseeva, et al.
Published: (2023-06-01)

Computational screening of MXene-based catalysts for chlorinated hydrocarbons removal
by: Miroslav Kolos, et al.
Published: (2025-01-01)

Super-Charged Natural Killer Cells: A Promising Immunotherapeutic Strategy for Oral Cancer
by: Kawaljit Kaur, et al.
Published: (2025-02-01)

Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review
by: Torchia A, et al.
Published: (2025-04-01)

Senescence, NK cells, and cancer: navigating the crossroads of aging and disease
by: Marina Gergues, et al.
Published: (2025-04-01)

Lower Number and Percentage of Activated Natural Killer Cells in Colorectal Cancer Patients
by: Amie Vidyani, et al.
Published: (2023-01-01)

NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells
by: Caterina Marangio, et al.
Published: (2025-05-01)

Correction: PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival
by: Jeremiah L. Oyer, et al.
Published: (2025-07-01)

PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival
by: Jeremiah L. Oyer, et al.
Published: (2024-04-01)

Prognostic significance of T cells and NK cells in osteosarcoma: a dual-center retrospective study
by: Kai Luo, et al.
Published: (2025-04-01)

Targeting ATF5, CEBPB, and CEBPD with Cell-Penetrating Dpep Sensitizes Tumor Cells to NK-92MI Cell Cytotoxicity
by: Qing Zhou, et al.
Published: (2025-05-01)

Patient engagement in radiation oncology: a large retrospective study of survey response dynamics
by: Bailey A. Loving, et al.
Published: (2025-01-01)

Does a natural killer need a CAR?
by: Kangbo Wang, et al.
Published: (2025-06-01)

Over-activation and dysfunction of platelet-NK cell aggregates in HIV-infected individuals
by: Meiju Deng, et al.
Published: (2025-05-01)

Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review
by: Xiaoqian Zhao, et al.
Published: (2025-08-01)

Immunological alterations in patients with primary tumors in central nervous system
by: MARIA TEREZINHA S. PERAÇOLI, et al.
Published: (1999-09-01)

Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions
by: Michelle L. McKeague, et al.
Published: (2024-10-01)

Changes in immune status of circulating NK cells in patients with latent tuberculosis infection
by: Shuang Qin, et al.
Published: (2024-08-01)

Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma
by: Chang Shan, et al.
Published: (2025-07-01)

Development and Validation of the Interpreting Learning Engagement Scale (ILES)
by: Wenting Yu, et al.
Published: (2024-12-01)